Wepox 10000IU/ml Injection contains Recombinant Human Erythropoietin Alfa at a concentration of 10000IU/ml, a glycoprotein hormone that stimulates erythropoiesis, the production of red blood cells. It is indicated for the treatment of anemia associated with chronic kidney disease (CKD), including patients on dialysis and those not yet on dialysis, as well as anemia due to chemotherapy in cancer patients. Wepox acts by binding to erythropoietin receptors on erythroid progenitor cells in the bone marrow, promoting their proliferation and differentiation, thereby increasing hemoglobin levels and reducing the need for blood transfusions. The injection is administered subcutaneously or intravenously, with dosage individualized based on patient response and hemoglobin targets. Monitoring of hemoglobin, hematocrit, blood pressure, and iron status is essential during therapy to optimize efficacy and minimize adverse effects. Common side effects include hypertension, headache, arthralgia, and injection site reactions. Wepox should be used cautiously in patients with uncontrolled hypertension or hypersensitivity to erythropoietin products. Adequate iron supplementation is recommended to support effective erythropoiesis. This product should be stored under recommended conditions and used under medical supervision to ensure safe and effective treatment of anemia.